Skip to main content

Table 1 Eligibility criteria for relevant studies

From: Comparison of transcatheter aortic valve implantation with other approaches to treat aortic valve stenosis: a systematic review and meta-analysis

  Eligibility criteria
Populations • Adult patients with severe, symptomatic, native aortic valve stenosis
• Any risk profile (high, intermediate, low)
Intervention • Transcatheter aortic valve implantation (TAVI) for native aortic valve stenosis with:
 - Any commercial-used valve device
 - Any transvascular or transapical percutaneous approach
 - With or without concomitant percutaneous coronary intervention
Comparators • Surgical aortic valve replacement
 - Any valve devices and surgical approaches (conventional, minimally invasive)
 - With or without concomitant intervention (coronary aortic bypass grafting)
• Medical therapy (MT)
• Balloon aortic valvuloplasty
Outcomes • Efficacy and effectiveness
 - Mortality 30 days
 - Mortality 1 year
• Safety
 - Stroke 30 days, 1 year
 - Transient ischemic attack 30 days
 - Myocardial infarction 30 days
 - Major bleeding 30 days
 - Major vascular complications 30 days
 - Severe or moderate paravalvular aortic regurgitation 30 days
 - New pacemaker implantation 30 day
We included efficacy, effectiveness, and safety outcome reported as in-hospital, perioperative, or postoperative.
Timing • Minimum follow-up duration of 30 days
Study designs • Randomized controlled trials
• Non-randomized controlled trials
• Controlled cohort studies with propensity score-matching
• For all eligible study designs, 100 patients or more in the TAVI arm
We excluded case reports, case series, and any study without control group and fewer than 100 patients in the TAVI arm.
Publication type • Publication reporting primary data
We excluded publications not reporting primary data (narrative reviews, systematic reviews, and meta-analysis) as well as abstracts only, letters, and editorials.
Publication language • English, German